Publication: Immunohistochemical evaluation of versican, in relation
to chondroitin sulphate, in canine mammary tumours
Authors
Erdélyi, I. ; Nieskens, D.H.M. ; van Dijk, J.E. ; Vass, L. ; Nederbragt, H.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The expression of increased amounts of
versican, a chondroitin sulphate proteoglycan, in
neoplastic tissues may play a role in promoting tumour
cell proliferation and migration. This study investigated
the immunolocalization of versican in normal and
neoplastic canine mammary tissues, using antibodies
12C5 and 2B1, against different epitopes of the protein
core of versican. Antibody CS56, recognising
chondroitin sulphate (CS), was used to investigate the
relation between versican and CS, which accumulates in
canine mammary tumours. We found enhanced versican
expression in both benign and malignant tumours,
appearing in three main patterns: in periductal tissues,
probably in association with basement membranes of
ducts; in peripheral invasive areas of malignant tumours;
and in spindle cell proliferations and myxoid areas of
complex and mixed tumours. The 12C5 and 2B1
immunoreactivities co-localised in all types of tumours,
and could be improved by chondroitinase digestion. The
only exception was the abundant extracellular matrix
(ECM) of spindle cell proliferations, particularly in
myxoid areas of complex and mixed tumours, which
displayed intense and diffuse 12C5 immunoreactivity
and patchy or absent 2B1 and CS56 immunoreactivities;
versican immunoreactivity could not be enhanced by
chondroitinase digestion. The results indicate that
versican is one of the extracellular matrix components
characteristic of canine mammary tumours. It appears
likely that in complex and mixed tumours versican exists
in at least two forms, one of them lacking the CS
attachment domain and the 2B1 epitope. Furthermore,
the enhanced versican expression in the invasive areas of
malignant tumours indicates the involvement of this
proteoglycan in tumour cell invasion.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.